Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects

NCT02342704 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT02342704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02342704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects
Lead sponsor
Biogen
Phase
Phase 4
Overall status
Terminated
Start date
November 30, 2014
Completion date
May 18, 2016
Enrollment
111 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing-remitting multiple sclerosis